secwatch.observer — SEC 8-K summary
======================================

Issuer:     Baudax Bio, Inc. (—)
CIK:        0001780097
Form:       8-K
Filed at:   2023-10-25T23:59:59+00:00
Accession:  0001193125-23-262285
Event type: other_material
Sentiment:  negative
Materiality: 0.70
Item codes: 4.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Baudax Bio dismisses EisnerAmper as auditor, engages KPMG; cites material weakness
--------------------------------------------------------------------------------

- Dismissed EisnerAmper on Oct 19, 2023; KPMG appointed as new independent auditor for FY 2023.
- EisnerAmper's 2022 report included a going-concern paragraph citing $190.9M accumulated deficit.
- Material weakness identified in Q2 2023 related to purchase price accounting for TeraImmune acquisition; no restatement.
- No disagreements between Company and EisnerAmper; KPMG previously served as auditor from 2019 to June 2022.
- Audit committee recommended change after competitive review; EisnerAmper letter filed as Exhibit 16.1.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1780097/000119312523262285/0001193125-23-262285-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1780097/000119312523262285/d564363d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-262285

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer